Verdict: Noventra Limited, still trading under LOTCHEM and formerly named Lotte Chemical Pakistan Limited, delivered a powerful nine-month earnings recovery, but the September quarter itself was much less convincing. Nine-month profit after tax rose almost sixfold to Rs4.85 billion as gross profit widened and other income surged. In Q3 alone, however, revenue, gross profit and operating profit all fell year on year, while most of the increase in net profit came below the operating line.
That distinction matters. The cumulative result shows a materially better 2026 than the weak 2025 base, but the latest quarter shows the operating rebound losing force. Q3 gross margin slipped to 2.68% and operating margin to 0.75%, even as profit after tax increased to Rs539 million because other income reached Rs1.05 billion. The result is therefore strong at the nine-month level but low-quality in the latest quarter unless the other-income contribution proves recurring.
All figures below are from the company’s unaudited, unconsolidated financial statements for the quarter and nine months ended 30 September 2026 and are stated in Pakistani rupees. Income-statement and balance-sheet figures are presented in Rs million unless stated otherwise.
Results at a glance
- Nine-month revenue increased 4.4% to Rs63.18 billion, while gross profit climbed 160.8% to Rs6.12 billion. Gross margin expanded to 9.69% from 3.88%.
- Nine-month operating profit rose 240.5% to Rs4.66 billion, and profit after tax increased 480.4% to Rs4.85 billion. EPS rose to Rs3.20 from Rs0.55.
- Q3 revenue fell 9.3% year on year to Rs18.47 billion. Gross profit declined 13.1% to Rs496 million and operating profit fell 33.1% to Rs138 million.
- Q3 profit after tax still rose 473.0% to Rs539 million, but this was driven by Rs1.05 billion of other income versus Rs88 million a year earlier. Finance cost more than doubled to Rs361 million.
- The board recommended no new cash dividend, bonus issue or rights issue with the September result.
AlphaGen model scores
Alpha QoQ Score: 21.41. TTM Performance Score: 92.46. 3Y Business Perf Score: 43.22. Sector Leadership Score: 62.50. These are AlphaGen model outputs, not figures reported by the company, and they should be read as analytical indicators rather than accounting measures.
What improved
The nine-month gross-profit recovery was real and material
The clearest operating improvement is visible in the nine-month cost structure. Revenue grew by Rs2.63 billion, but cost of sales fell by Rs1.14 billion to Rs57.05 billion. That combination lifted gross profit by Rs3.78 billion and widened gross margin by 581 basis points. The arithmetic indicates a substantially better spread between sales and production costs across the first nine months of 2026.
The result attachment does not include the detailed notes that would separate volume, PTA pricing, paraxylene input costs, energy costs, inventory effects or exchange-rate movements. It would therefore be speculative to assign the margin recovery to any one of those factors. What can be stated confidently is that the improvement came primarily through cost of sales rather than rapid top-line growth.
Operating leverage amplified the recovery
Distribution, administrative and other operating expenses collectively rose to about Rs1.46 billion from Rs979 million, but the Rs3.78 billion expansion in gross profit comfortably absorbed that increase. Operating profit consequently rose from Rs1.37 billion to Rs4.66 billion, and operating margin increased to 7.38% from 2.26%. This is a meaningful improvement in the cumulative operating result even after higher overhead and other operating charges.
Other income added a second, very large earnings leg
Other income increased to Rs4.09 billion for the nine months from Rs463 million. That Rs3.63 billion uplift was almost as large as the gross-profit increase. It helped profit before tax reach Rs7.91 billion, up from Rs1.37 billion. Finance cost rose 83.5% to Rs840 million, but the combined gross-profit and other-income gains were much larger.
This is also the article’s most important evidence limitation. The result announcement references note 16 for other income, but the five-page attachment does not contain the accompanying notes. The precise mix of finance income, foreign-exchange effects, disposal gains or other items cannot be verified from the released summary. The article therefore treats other income as reported but does not classify it as recurring.
Nine-month operating cash flow turned positive
Net cash generated from operating activities was Rs607 million, compared with Rs5.40 billion used in the comparable period. The roughly Rs6.01 billion swing is directionally positive and shows that the income-statement improvement was not accompanied by another large operating cash outflow. It was nevertheless modest relative to Rs4.85 billion of profit after tax, so cash conversion remained limited.
What weakened / needs attention
The latest quarter was an operating setback
Q3 revenue declined to Rs18.47 billion from Rs20.37 billion. Gross profit fell to Rs496 million from Rs570 million, lowering gross margin to 2.68% from 2.80%. Operating profit dropped to Rs138 million from Rs206 million, and operating margin narrowed to 0.75% from 1.01%. These are not catastrophic declines, but they show that the strong nine-month margin was built mainly in the first half rather than sustained through September.
The sequential comparison is sharper. Against Q2 2026, Q3 revenue fell 22.6%, gross profit dropped 81.6%, operating profit fell 94.2% and profit after tax declined 81.0%. Seasonal or shutdown effects may be relevant, but the filing does not disclose enough operational detail to establish the cause. The defensible conclusion is simply that quarterly earnings momentum deteriorated materially.
Quarterly net profit depended on non-operating support
Q3 other income rose almost twelvefold to Rs1.05 billion, while finance cost increased 136.6% to Rs361 million. Operating profit of Rs138 million alone would not have supported the reported Rs829 million profit before tax. The quarter’s net margin rose to 2.92% from 0.46%, but that improvement should not be confused with stronger manufacturing profitability because operating margin moved in the opposite direction.
This makes the next disclosure of note 16 particularly important. If the other-income increase is largely recurring finance income or an enduring operational credit, the quarter is more sustainable than it appears. If it is dominated by one-off gains, normalized earnings would be materially lower. Until the note is published, the result should be read with that uncertainty explicit.
Finance costs and borrowing moved higher
Borrowings were Rs5.70 billion at 30 September, comprising Rs4.03 billion of long-term borrowing and Rs1.67 billion of its current portion. At December 2025, total debt was only Rs800 million of short-term financing. Cash and short-term investments together were Rs2.17 billion at September, leaving calculated net debt of roughly Rs3.53 billion versus a substantial net-cash position at year-end.
The cash-flow statement shows Rs6.51 billion of long-term borrowing proceeds, Rs718 million of repayments and Rs90 million of transaction costs. The result does not state the exact purpose of the borrowing in the attached pages. It should not automatically be attributed to the announced Engro Polymer & Chemicals transaction without a specific note or transaction filing that ties the funding to that acquisition.
Balance sheet, dividends and cash flow
The balance sheet contracted materially. Total assets declined 24.9% from December to Rs35.88 billion, while equity fell 21.2% to Rs18.54 billion. The equity decline was not caused by a loss: the company earned Rs4.85 billion, but recognized Rs9.84 billion of dividends against reserves, comprising Rs5.00 per share for 2025 and Rs1.50 per share for 2026.
Liquidity ratios improved despite the lower cash balance because current liabilities fell much faster than current assets. Current assets declined 26.5% to Rs28.49 billion, but current liabilities fell 57.1% to Rs10.32 billion. The reported-line current ratio therefore improved to approximately 2.76 times from 1.61 times. Inventory fell 54.6% to Rs4.13 billion, trade debts declined 32.7% to Rs4.31 billion and trade and other payables fell 62.3% to Rs8.46 billion.
Those working-capital reductions helped operations generate cash, but capital allocation absorbed it. Capital expenditure rose to Rs1.44 billion from Rs495 million, and dividend payments reached Rs9.82 billion. After borrowing proceeds, financing activities still used Rs5.25 billion. Cash and cash equivalents consequently fell by Rs6.07 billion during the nine months to Rs2.17 billion.
Business and strategic context
Noventra describes itself as Pakistan’s sole domestic manufacturer of purified terephthalic acid, with annual capacity above 500,000 tonnes. PTA is a feedstock for polyester fibre, PET packaging and film, linking the company’s operating performance to downstream textile and packaging demand as well as the spread between PTA selling prices and paraxylene and energy costs.
The company announced on 1 September 2026 an agreement to acquire Engro Corporation’s 56.19% holding in Engro Polymer & Chemicals for Rs19.7 billion, followed by a mandatory tender offer and an intended merger, subject to approvals and closing conditions. The strategic logic is diversification from PTA into PVC and related chemicals. Because the transaction had not been shown as completed in the September result attachment, it is a forward-looking monitoring item rather than an explanation for the reported quarter.
The name change to Noventra Limited reflects the post-Lotte ownership transition; the PSX ticker remains LOTCHEM at the time of this result. The official filing itself uses “Noventra Limited (formerly Lotte Chemical Pakistan Limited),” while some market records still display the former name.
What to monitor next
- The composition and repeatability of the Rs4.09 billion nine-month other-income balance, especially the Rs1.05 billion recognized in Q3.
- Whether gross margin recovers from Q3’s 2.68% level and moves back toward the 9.69% nine-month average without exceptional support.
- The trajectory of finance cost after the increase in borrowings, and whether new debt is linked to working capital, capital expenditure or the proposed EPCL acquisition.
- Operating cash conversion after a positive but modest Rs607 million nine-month inflow, together with the impact of lower inventories, receivables and payables.
- Regulatory approvals, tender-offer terms, financing and completion conditions for the proposed EPCL transaction; none should be treated as completed until officially confirmed.
- Any new dividend decision. The September board announcement declared no additional payout after substantial earlier dividend distributions.
Evidence coverage and limitations
Evidence assessment: PASS WITH DISCLOSED LIMITATIONS. Identity, period, reporting basis, current earnings, comparative figures, balance sheet and nine-month cash flow are verified from the official PSX filing. The missing detailed notes prevent a defensible split of price, volume, feedstock, energy, foreign exchange and the components of other income. Those causal claims are deliberately omitted. Quarterly cash flow is not separately reported, so no claim is made about Q3 cash conversion.
Primary sources
PSX financial-result filing for the quarter and nine months ended 30 September 2026
Pakistan Stock Exchange company page for LOTCHEM
Noventra official company website and current corporate identity
Company announcement of the proposed Engro Polymer & Chemicals acquisition